Emerson Electric
EMR
$161.47
-0.42%
Emerson Electric Co. is a global industrial automation company that designs and sells automation software, control systems, valves, gauges, switches, and instrumentation across seven reporting segments, serving process, hybrid, and discrete manufacturing end markets. Following the divestiture of its climate technology and consumer businesses, Emerson has repositioned itself as a more focused pure-play automation and intelligent-devices platform, competing with the likes of Honeywell, Rockwell Automation, and Siemens in factory and process automation. The current investor narrative centers on whether this portfolio transformation can deliver durable mid-single-digit organic growth and margin expansion, with the most recent quarter showing revenue up roughly 7% year over year and gross margins improving sequentially to about 54.5%. Bulls point to automation software mix, pricing power, and a leaner cost structure, while skeptics flag soft order trends, a leveraged balance sheet from prior deal-making, and a valuation that already discounts a fair amount of operational improvement.…
EMR
Emerson Electric
$161.47
Related headlines
EMR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $174.96 and implied upside of +8.4% versus the current price.
Average Target
$174.96
0 analysts
Implied Upside
+8.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $205
Analyst target range
Coverage is broad, with 28 analysts following Emerson and a consensus recommendation of "buy" (mean rating of 1.9 on a 1-to-5 scale where 1 is a strong buy). The average target price of $174.79 implies roughly 8.2% upside from the current $161.47, a moderate rather than aggressive bullish signal, and the consensus EPS estimate of $9.42 on average revenue of $22.98 billion (range $22.35-$23.54 billion) frames the expected growth path. Sentiment leans constructive but not euphoric, consistent with a high-quality large-cap where much of the near-term upside is already reflected in the price. The target range is wide, from a low of $104.00 to a high of $205.00 — a spread of roughly 97% of the current price — which signals meaningful disagreement about the durability of the automation cycle and margin trajectory. The high target of $205 implies about 27% upside and would require multiple expansion toward the mid-20s forward PE alongside accelerating orders and software mix gains; the low target of $104 implies roughly 36% downside and prices in margin compression, a cyclical industrial slowdown, or integration/leverage setbacks. Recent institutional actions are mixed: JP Morgan upgraded to Overweight from Neutral in July 2026, while Morgan Stanley maintained Underweight and TD Cowen stayed at Hold in September, and Bernstein, Evercore, RBC, and Citigroup reiterated Outperform/Buy ratings in August — a pattern of stable-to-improving sentiment with a persistent bearish minority that keeps the consensus from becoming crowded.
Drowning in data?
Find the real signal!
Bulls vs Bears: EMR Investment Factors
The bull case currently has the stronger evidence: revenue is growing 7.03% with gross margins expanding to 54.48%, EPS is up 23% year over year, free cash flow is $3.46 billion TTM, and the stock is demonstrating genuine relative-strength leadership (13.03 points over three months versus SPY). The bear case rests less on deteriorating fundamentals than on price: at 22.20x forward earnings and 17.78x EV/EBITDA, EMR already discounts continued margin expansion, and the 97%-wide analyst target range ($104-$205) shows the market has not settled on how durable the automation cycle is. The single most important tension is whether the margin trajectory — gross margin up from 51.88% to 54.48% over four quarters — can be sustained as the company laps easy comparisons; if it can, the premium multiple is earned, but if it stalls, the 32.23x trailing PE has meaningful room to compress. Balance sheet leverage (D/E 0.678) and a sub-1.0 current ratio add a secondary layer of vulnerability in a downturn.
Bullish
- Earnings growth outpacing revenue: Q3 diluted EPS of $1.28 rose 23% from $1.04 a year earlier while revenue grew only 7.03%, demonstrating real operating leverage. The forward PE of 22.20x versus trailing 32.23x implies the market expects roughly $9.42 in forward EPS versus the current run-rate, a compression of about 31% that reflects confidence in continued earnings acceleration.
- Margin expansion is measurable and sequential: Gross margin climbed to 54.48% in Q3 from 53.09% in Q2 and 51.88% in the year-ago Q4, while operating margin rose to 20.54% from 19.75% sequentially. EBITDA margin of 24.73% and net margin of 14.73% confirm the improvement is flowing through the P&L rather than being a one-line anomaly.
- Strong free cash flow funds shareholder returns: TTM free cash flow of $3.46 billion with Q3 FCF of $1.322 billion on just $102 million of capex shows a highly cash-generative model. The company returned $311 million in dividends and $356 million in buybacks in the quarter, and the 51.98% payout ratio leaves room for further increases.
- Momentum leadership versus the index: EMR is up 25.28% over the past year versus SPY's 15.53%, and 10.72% over the past month versus just 1.22% for the index — a 9.50-point relative-strength spread. The 3-month relative strength of 13.03 points confirms this is broadening leadership, not a single-window anomaly.
Bearish
- Valuation leaves little margin for error: At 22.20x forward earnings, 17.78x EV/EBITDA, and 4.10x P/S, EMR trades roughly 10-20% above mature industrial machinery peers on forward earnings and well above the sector's low-teens EBITDA and mid-single-digit sales multiples. The PEG of 1.78 means growth is being paid for at a premium, so any deceleration would compress the multiple.
- Wide analyst dispersion signals uncertainty: The target range spans $104 to $205 — a spread of roughly 97% of the current price — which is unusually wide for a large-cap industrial. Morgan Stanley maintained Underweight and TD Cowen stayed at Hold in September 2026, a persistent bearish minority that reflects genuine disagreement about the durability of the automation cycle.
- Balance sheet is levered from deal-making: Debt-to-equity of 0.678 and a current ratio of 0.876 (below 1.0) reflect the leveraged profile left by prior acquisitions. Interest coverage of 11.8x is comfortable but interest expense of $85 million in Q3 is a real drag, and a cyclical downturn would pressure both the ratio and refinancing terms.
- Recent momentum looks stretched short-term: The 1-month gain of 10.72% is the steepest of all measured windows, and the stock sits at 88.6% of its 52-week range, just 2.9% below the $166.35 high. With a beta of 1.207 and a max drawdown of -23.74% over the period, a digestion phase or risk-off rotation could hit the shares disproportionately.
EMR Technical Analysis
Emerson is in a sustained uptrend, with the stock up 25.28% over the past year and 18.89% year to date, materially outpacing the S&P 500's 15.53% and 11.93% respective gains. At $161.47, the shares sit at roughly 88.6% of the 52-week range of $122.64 to $166.35, positioning them in the upper portion of the band but still about 2.9% below the high, which suggests momentum leadership rather than an overextended blow-off top. The 180-day price series confirms a staircase pattern of higher lows from the April trough near $130.65 to the October consolidation above $160. Recent momentum is clearly accelerating: the stock is up 10.72% over the past month versus just 1.22% for SPY, a 9.50-point relative-strength spread, and up 15.72% over three months against 2.69% for the index (13.03 points of relative strength). This short-term outperformance is consistent with, not divergent from, the longer-term trend, and the 6-month gain of 10.33% versus SPY's 7.48% shows the leadership is broadening rather than narrowing. The one caution is that the 1-month surge is the steepest of the measured windows, which often precedes short-term digestion. Key resistance sits at the 52-week high of $166.35, roughly 3.0% above the current price; a decisive breakout on volume would confirm the uptrend and likely open a measured move toward the $175-$180 zone. Support is anchored at the 52-week low of $122.64, with intermediate support in the $145-$150 area where the stock consolidated in September. With a beta of 1.207, Emerson is about 21% more volatile than the market, and its maximum drawdown of -23.74% over the period underscores that position sizing should account for amplified downside in risk-off regimes. The short ratio of 3.7 days is moderate and not a meaningful squeeze catalyst.
Beta
1.21
1.21x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$166
Price range past year
Annual Return
+25.3%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +0.2% |
| 3m | +15.7% | +2.9% |
| 6m | +10.3% | +8.4% |
| 1y | +25.3% | +14.9% |
| ytd | +18.9% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue is growing at a healthy clip: fiscal Q3 2026 (quarter ended June 30, 2026) revenue reached $4.873 billion, up 7.03% year over year from $4.553 billion, and up sequentially from $4.562 billion in Q2 and $4.346 billion in Q1. The multi-quarter trajectory shows steady expansion, with quarterly revenue climbing from $4.175 billion in the December 2024 quarter to the latest $4.873 billion, and the segment mix is led by Intelligent Devices at $2.677 billion, followed by Software and Systems at $1.644 billion and Final Control at $552 million. Growth is being driven by the core intelligent-devices and software franchises rather than any single cyclical pocket, which supports the thesis that Emerson's automation repositioning is translating into durable top-line momentum. Profitability is solid and improving: Q3 net income was $718 million on a 14.73% net margin, gross margin rose to 54.48% from 53.09% in Q2 and 51.88% in the year-ago Q4, and operating margin reached 20.54%, up from 19.75% in Q2. EBITDA of $1.205 billion equates to a 24.73% EBITDA margin, and diluted EPS of $1.28 grew from $1.04 a year earlier, a 23% increase that reflects both operating leverage and a lower share count (561.1 million diluted versus 564.7 million). The margin trajectory is clearly upward, consistent with a premium industrial automation franchise that typically earns gross margins in the low-to-mid 50s. The balance sheet is sound but not fortress-like: debt-to-equity is 0.678, the current ratio is 0.876 (below 1.0, reflecting a working-capital profile typical of the sector), and interest coverage is a comfortable 11.8x. Free cash flow is robust at $3.46 billion TTM, with Q3 FCF of $1.322 billion on operating cash flow of $1.424 billion against capex of just $102 million, and the company returned capital via $311 million of dividends and $356 million of buybacks in the quarter. ROE of 11.31% and ROA of 6.90% are respectable though not exceptional, and the dividend payout ratio of 51.98% with a 1.61% yield leaves room for continued increases while still funding growth internally.
Quarterly Revenue
$4.9B
2026-06
Revenue YoY Growth
+7.0%
YoY Comparison
Gross Margin
54.5%
Latest Quarter
Free Cash Flow
$3.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Because Emerson is solidly profitable (Q3 net income of $718 million, TTM EPS positive), the PE ratio is the appropriate primary metric. The stock trades at 32.23x trailing earnings but only 22.20x forward earnings, a roughly 31% compression that implies the market expects meaningful EPS growth — consistent with the consensus estimate of $9.42 for the forward period versus the current run-rate. The PEG ratio of 1.78 suggests the growth is being paid for at a modest premium to a fair-growth benchmark, while the EV/EBITDA of 17.78x and P/S of 4.10x round out a valuation that is full but not extreme for a quality industrial compounder. Against the industrial machinery sector, where mature peers typically trade in the high-teens to low-20s on forward earnings, Emerson's 22.2x forward PE represents a modest premium of roughly 10-20%, and its 4.10x P/S and 17.78x EV/EBITDA sit above the sector's typical mid-single-digit sales and low-teens EBITDA multiples. That premium is defensible given the 54.5% gross margin, 20.5% operating margin, and 7% organic growth — all above the average for diversified machinery — but it leaves little room for execution missteps. On its own history, the current 32.2x trailing PE compares favorably to the 46.95x and 97.8x readings seen in 2023-2024 when earnings were depressed by restructuring, and is roughly in line with the 29-32x band that has prevailed over the past several quarters; the P/S of 4.10x, however, is well below the 13-17x historical figures, largely a function of the post-divestiture revenue base. The takeaway is that valuation is near the middle-to-upper end of its recent band, pricing in continued margin expansion and mid-single-digit growth rather than a deep value opportunity.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the leveraged balance sheet and the dependence on continued margin expansion to justify the valuation. Debt-to-equity of 0.678 and a current ratio of 0.876 leave limited cushion, and while interest coverage of 11.8x is comfortable, Q3 interest expense of $85 million is a recurring drag on a $718 million net income base. The earnings multiple itself is a risk: at 32.23x trailing PE, the stock requires the forward EPS estimate of $9.42 to materialize, meaning any revenue miss that flows through to earnings would hit both the 'E' and the multiple simultaneously. ROE of 11.31% and ROA of 6.90% are not high enough to provide a valuation floor if growth decelerates.
Market and competitive risks are dominated by valuation compression and cyclical sensitivity. EMR trades at roughly a 10-20% premium to mature industrial machinery peers on forward earnings and well above the sector's typical low-teens EV/EBITDA, so a rotation out of premium industrials would hit the stock harder than the group. The beta of 1.207 means a 10% market decline would imply roughly a 12% decline for EMR, and the -23.74% max drawdown over the measured period shows that amplification is not theoretical. Competition from Honeywell, Rockwell Automation, and Siemens in factory and process automation, plus soft order trends flagged in the investor narrative, could pressure the pricing power that underpins the 54.48% gross margin. The persistent bearish minority — Morgan Stanley at Underweight and TD Cowen at Hold as of September 2026 — keeps a negative narrative alive that could gain traction on any order weakness.
In a worst-case scenario, a cyclical industrial slowdown would coincide with order softness, stall the margin expansion, and trigger multiple compression from 22.20x forward earnings toward the high-teens. The analyst low target of $104.00 implies roughly 36% downside from $161.47, and the 52-week low of $122.64 implies about 24% downside. A realistic adverse path — a demand slowdown plus a multiple reset to 18x on a modestly lowered EPS estimate — would put the stock in the $120-$130 zone, a loss of roughly 20-25% from current levels, with the $104 bear target representing the tail scenario if leverage and integration concerns compound the cyclical pressure.
